J44.9 J45
Conditions
Interventions
Group 1: COPD patients are asked about their quality of life using the CAT (COPD Assessment Test) questionnaire.
Sponsors
Chiesi GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Patients with moderate to severe COPD (with and without asthma). 2) The doctor made the decision for a therapy with Trimbow® within the scope of its German approval, regardless of the present study. 3) Patients who have had at least one COPD exacerbation within the 12 months prior to starting treatment with Trimbow®. 4) Patients who are willing and able to give their written consent to the use of their pseudonymised personal data for the purposes of the present study.
Exclusion criteria
Exclusion criteria: 1) Patients who were hospitalized for a COPD exacerbation within the last 4 weeks prior to inclusion. 2) Participation in a clinical trial within the last 30 days before inclusion in the present NIS.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary observation goal is to investigate the change in quality of life in COPD patients for whom the treating physician has decided to undergo therapy with Trimbow®. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary observation goal is to investigate adherence to COPD therapy, the reasons for non-adherence, the use of COPD reliever medication and the need to change COPD therapy before and during therapy with Trimbow®. Furthermore, changes in relevant lung function parameters as well as the retention of the Trimbow® treatment are to be examined. Furthermore, the aim of this study is to collect as complete as possible patient data from routine care for the purpose of generating hypotheses at a later point in time. | — |
Countries
Germany
Contacts
Public ContactValentina Bogoevska
CHIESI GmbH
Outcome results
None listed